Introduction

Restless leg syndrome (RLS), also known as Willis–Ekbom disease, is a neurological sensorimotor disorder accompanied by an irresistible urge to move the legs with a fluctuating course of symptoms. It is a common disorder affecting all ages, with existing comorbidities and positive family history being associated with increased prevalence. Herein, we present a case of a 51-year-old female diagnosed with the bipolar affective disorder who developed restless leg syndrome following the use of olanzapine. Olanzapine is a second-generation atypical antipsychotic which can cause restless leg syndrome due to its anti-dopaminergic action on the nervous system, particularly the spinal cord. Existing literature on olanzapine-induced restless leg syndrome has suggested managing this disorder by reducing the dose or replacing olanzapine with other drugs such as clonazepam, quetiapine, and aripiprazole. In our case, olanzapine was not replaced with other medications as the patient showed a significant improvement in bipolar affective disorder symptoms using olanzapine. Instead, clonazepam was added to the treatment regimen which was scheduled to be taken before olanzapine.

Case report

A 51-year-old female, with 24 years history of BD, presented to the psychiatric unit with her family. She was alert, had fair hygiene, and had good eye contact. Informants described her

Olanzapine was not replaced with other medications as the patient showed a significant improvement in BD symptoms using olanzapine. Instead, clonazepam was added to the treatment regimen which was scheduled to be taken before olanzapine.

Keywords

Case report, olanzapine, antipsychotic, restless leg syndrome, restless leg syndrome, second-generation antipsychotic, Willis–Ekbom disease
with increased psychomotor activity, tone, volume, and speech tempo, aggressiveness, irritability, muttering to self, decreased need for sleep, and frequent anger outbursts for 4 months, with worsened symptoms 3 weeks prior to presentation, suggestive of a manic episode of BD. The patient was oriented to person and place. She also had a history of nicotine use in the form of chewing betel leaf. Her mental status examination suggested a delusion of persecution and reference, second person auditory hallucinations, irritable mood, dysphoric affect, crying spells, impaired judgment, and absence of insight and impulse control.

On investigation, her complete hemogram showed an Hb concentration of 10.5 g/dL, and MCV 76.1 as shown in Table 1. Henceforth, she was also diagnosed to have IDA. Initial lithium concentration in the serum was undetectable. Other hematological and biochemical parameters, including blood sugar, MCHC, MCH, HCT/PCV, RBC count, platelet count, renal, liver, and thyroid function were within normal limits as shown in Table 1.

The patient was admitted to the inpatient psychiatric hospital for her manic symptoms, and risperidone was initiated at a dose of 2 mg, which was consequently titrated to 6 mg. The patient however developed postural hypotension, for which it was tapered and stopped. Lithium in the dose of 900 mg was given. However, the patient showed no improvements. Hence, lithium was cross-tapered with valproate, and valproate was titrated up to 1500 mg. As lithium and valproate both showed partial improvements, a combination of lithium and valproate was maintained. Olanzapine was started at a dose of 10 mg, which was increased to 30 mg after 3 days owing to partial improvement. The patient complained of irritative sensation in the bilateral calf muscles after 6 days of starting olanzapine 30 mg, which improved during movement, worsened on rest, and was particularly distressing at night. Diagnostic criteria from the International RLS Study Group (IRLSSG) are as follows:

1. An urge to move the legs usually but not always accompanied by or felt to be caused by uncomfortable and unpleasant sensations in the legs.
2. The urge to move the legs and any accompanying unpleasant sensations begin or worsen during periods of rest or inactivity such as lying down or sitting.
3. The urge to move the legs and any accompanying unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
4. The urge to move the legs and any accompanying unpleasant sensations during rest or inactivity only occur or are worse in the evening or night than during the day.
5. The occurrence of the above features is not solely accounted for as symptoms primary to another medical or behavioral condition (e.g. myalgia, venous stasis, leg edema, positional discomfort, and habitual foot tapping).

Based on the IRLSSG diagnostic criteria, the patient met all the criteria and was diagnosed with RLS, for which

| Table 1. Investigation and results. |
|-------------------------------------|
| Investigations                      | Result   | Normal reference range |
|-------------------------------------|----------|------------------------|
| Albumin/globulin ratio              | 1.2      | 0.8–2.0                |
| Alkaline phosphatase                | 105      | 44–147 IU/L            |
| Total serum bilirubin               | 0.31     | 0.1–0.2 mg/dl          |
| Serum globulin                      | 3.7      | 2.0–3.5 g/dl           |
| Total serum protein                 | 7.88     | 6–8.3 g/dL             |
| Basophils                           | 0.8      | 0.5%–1%                |
| Eosinophils                         | 9.2      | 1%–4%                  |
| Packed cell volume                  | 33.2     | 35.5%–44.9%            |
| Hemoglobin                          | 10.5     | 11.6–15 g/dL           |
| Lymphocytes                         | 20.2     | 20%–40%                |
| Mean corpuscular hemoglobin         | 31.7     | 32–36 g/dL             |
| Mean corpuscular volume             | 24.1     | 27–31 pg/cell          |
| Monocytes                           | 8.3      | 2%–8%                  |
| Neutrophils                         | 61.5     | 54%–62%                |
| Platelet count                      | 503      | 150–450 x 10³/mcL      |
| Erythrocyte count                   | 4.36     | 4.2–5.4 million cells/ mcL |
| Total leukocyte count               | 9.1      | 4.5–11 x 10⁹/L         |
| Ammonia plasma                      | 56       | 15–45                  |
| Serum valproate                     | 87       | 50–125 mcg/mL          |
| Serum lithium                       | 0.79 mEq/L | 0.6–1.2 mEq/L         |
clonazepam 1 mg/day was started, and instructed to take clonazepam before olanzapine. The patient showed improvement after the addition of clonazepam.

**Discussion**

In this patient, we considered a differential diagnosis of volitional movements, akathisia, leg cramps, psychogenic cause, and peripheral neuropathy. Although there was no significant family history of RLS in the patient, she had IDA, which is associated with increased prevalence and severity of RLS. Also, it is possible that IDA leads to alteration of dopaminergic receptor profile and contributes to RLS. Since the symptoms suggesting RLS began only after a few days of administration of olanzapine, and her IDA existed before her admission to the hospital, we suspected olanzapine to be the root cause for her RLS with IDA worsening the severity of the syndrome. She was managed with iron supplementation, and clonazepam to treat RLS along with her drug regimen for BD.

Basu et al. and Aggarwal et al. reported symptoms of RLS on 15 mg/day of olanzapine. Other studies reported symptoms of RLS in patients on 20 mg/day of olanzapine. Also, Kraus et al. found symptoms of RLS on 20 mg/day of olanzapine in a female in her fifties diagnosed with BD. So far, olanzapine-induced akathisia has been reported in both males and females with bipolar disorder or schizophrenia. In our case, the patient was a female in her 50s, diagnosed with BD, and reported symptoms after 6 days of olanzapine at 30 mg/day.

It is hypothesized that olanzapine can lead to RLS due to its anti-dopaminergic action on the nervous system, particularly the spinal cord. It is interesting to note that risperidone, an anti-dopaminergic drug, was used in our case. However, the patient did not show RLS following the use of risperidone. This warrants further investigation into the probable mechanism leading to RLS, which may reveal other possible mechanisms leading to this condition.

Earlier cases of olanzapine-induced RLS were managed by reducing the dose or replacing olanzapine with other drugs such as clonazepam, quetiapine, and aripiprazole depending on the response. Kraus et al. managed the condition by replacing olanzapine with quetiapine. In a case series of five patients, the management was done by either reducing the dose, stopping the drug, or replacing it with alternatives such as ropinirole and clonazepam. In another case series, patients were managed by replacing olanzapine with risperidone, quetiapine, or aripiprazole. In our case, we did not replace olanzapine, as the patient showed improvement in BD. Instead, we added clonazepam before taking olanzapine as it was a safe drug for these patients and effective in treating RLS.

**Conclusion**

We present the case of a female in her 50s diagnosed with the BD who developed RLS after using olanzapine 30 mg/day for 6 days. The addition of clonazepam before taking olanzapine was given to manage RLS in the context of olanzapine. Olanzapine dose was not decreased as the patient showed improvement in BD symptoms. This case adds to the existing literature on diagnosing and managing olanzapine-induced RLS. Our case showed that RLS could be managed by adding benzodiazepines without switching, stopping, or decreasing the dosage of antipsychotics such as olanzapine if the patient shows improvement in psychiatric symptoms using antipsychotics like olanzapine.

**Acknowledgements**

The authors express their gratitude to the patient for her consent to publish this report.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Ethics approval**

Our institution does not require ethical approval for reporting individual cases or case series.

**Informed consent**

Written informed consent was obtained from the patient for their anonymized information to be published in this article. Patient regained fair insight and judgment over the course of her treatment regime to provide written informed consent by herself.

**ORCID iDs**

Sakshi Prasad https://orcid.org/0000-0002-1014-9031
Ayush Anand https://orcid.org/0000-0003-0279-4636

**References**

1. International Restless Legs Syndrome Study Group (IRLSSG). Diagnostic criteria, http://irlssg.org/diagnostic-criteria/ (2012, accessed 25 June 2022).
2. Trenkwalder C, Paulus W and Walters AS. The restless legs syndrome. *Lancet Neurol* 2005; 4: 465–475.
3. Lv Q, Wang X, Asakawa T, et al. Pharmacologic treatment of restless legs syndrome. *Curr Neuropharmacol* 2021; 19(3): 372–382.
4. Kotagal S and Silber MH. Childhood-onset restless legs syndrome. *Ann Neurol* 2004; 56: 803–807.

5. Pienczk-Ręcławowicz K, Pilarska E, Olszewska A, et al. The prevalence of the restless legs syndrome/Willis-Ekbom disease among teenagers, its clinical characteristics and impact on everyday functioning. *Sleep Med* 2022; 89: 48–54.

6. McArdle N, Reynolds AC, Hillman D, et al. Prevalence of common sleep disorders in a middle-aged community sample. *J Clin Sleep Med* 2022; 18: 1503–1514.

7. Innes KE, Selfe TK and Agarwal P. Prevalence of restless legs syndrome in North American and Western European populations: a systematic review. *Sleep Med* 2011; 12(7): 623–634.

8. Allen RP, Auerbach S, Bahrain H, et al. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. *Am J Hematol* 2013; 88(4): 261–264.

9. Bae H, Kim KT, Heo MH, et al. The prevalence and clinical characteristics of restless legs syndrome in patients with iron deficiency anemia in Korea. *J Clin Sleep Med* 2021; 17: 1447–1452.

10. Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. *Sleep Med* 2016; 21: 1–11.

11. Basu A, Kundu S and Khurana H. Olanzapine-induced restless leg syndrome: a case report and review of literature. *Indian J Pharmacol* 2014; 46(4): 450–452.

12. Aggarwal S, Dodd S and Berk M. Restless leg syndrome associated with olanzapine: a case series. *Curr Drug Saf* 2010; 5(2): 129–131.

13. Kraus T, Schulz A and Pollmächer T. Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. *J Clin Psychopharmacol* 1999; 19(5): 478–479.

14. Khalid I, Rana L, Khalid TJ, et al. Refractory restless legs syndrome likely caused by olanzapine. *J Clin Sleep Med* 2009; 5: 68–69.

15. Kang SG, Lee HJ and Kim L. Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine. *J Psychopharmacol* 2009; 23(5): 597–601.

16. Roshi R, Tandon V, Mahajan A, et al. Comparative efficacy and safety of clonazepam versus nortriptyline in restless leg syndrome among forty plus women: a prospective, open-label randomized study. *J Midlife Health* 2019; 10(4): 197–203.